+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Entyvio

  • ID: 4775310
  • Report
  • 37 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Entyvio (vedolizumab; Takeda) is a monoclonal antibody approved for the treatment of Crohn’s disease.

It inhibits the alpha-4-beta-7 integrin receptor, preventing the migration of T cells to the gut.

T cells have been shown to play a role in mediating the inflammatory process in Crohn’s disease.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Entyvio: Crohn's disease
Entyvio: Ulcerative colitis

LIST OF FIGURES
Figure 6: The authors drug assessment summary of Entyvio in Crohn’s disease
Figure 19: The authors drug assessment summary of Remicade in Crohn’s disease
Figure 5: The authors drug assessment summary of Entyvio in Crohn’s disease
Figure 7: Humira for Crohn’s disease – SWOT analysis
Figure 23: The authors drug assessment summary of Tysabri in Crohn’s disease

LIST OF TABLES
Table 1: Entyvio drug profile
Table 2: Entyvio pivotal trial data in Crohn’s disease
Table 3: Entyvio ongoing late-phase trials in Crohn’s disease
Table 14: Entyvio ongoing late-phase trials in Crohn’s disease
Table 5: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 6: Entyvio drug profile
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll